{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"}]}],"title":"Complete response + Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"}]}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"}]}],"title":"Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.8"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5"}]}],"title":"Progressive disease measurement proven"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8"}]}],"title":"Progression by clinical judgement"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9"}]}],"title":"Not evaluated"}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"CR-disappearance of clinical/radiological tumor evidence (target/nontarget). PR- \\>=30% decrease in sum longest diameter (LD) of target lesions from BL sum LD. Stable disease (SD)-no shrinkage for PR nor increase for PD. Progressive disease (PD) measurement proven- \\>=20% increase in sum LD of lesions from smallest sum LD since start or new lesions. Progression by clinical judgement- \\>clinically meaningful cancer-related deterioration as judged by the investigator.","groups":[{"description":"Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (bid, bis in die) X 28 day cycles","id":"OG000","title":"Sorafenib"}],"paramType":"NUMBER","populationDescription":"The analysis population for the intent to treat (ITT) and safety analyses consisted of 52 subjects who received at least 1 treatment and had their disease re-evaluated. 51 subjects were considered evaluable since 1 of the 52 subjects had lung metastases from pancreatic cancer.","reportingStatus":"POSTED","timeFrame":"First patient first treatment until date for last data collection for efficacy for a study period up to 62 weeks. Tumor assessed per RECIST at baseline (BL), every 8 weeks during treatment and at end of treatment.","title":"Anti-cancer Activity (eg, Percentage of Patients With Confirmed Complete Responses (CR) and Partial Responses (PR) Per RECIST (Response Evaluation Criteria in Solid Tumors) Criteria in Patients With Stage IV Non-small Cell Lung Carcinoma (NSCLC)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}